Lupin has filed an Investigational New Drug Application (INDA) for a botanical oral treatment for psoriasis, Desoris (LLL-3348) with the Drug Controller General of India (DCGI).

Psoriasis is characterized by defects in the normal growth cycle of epidermis that lead to epidermal hyper-proliferation, altered maturation skin cells, vascular changes, and inflammation.

Based on animal data, Desoris (LLL-3348) has been found to be efficacious and safe. Some of the current treatments for psoriasis involve certain side effects such as nephrotoxicity, hepatotoxicity, bone marrow toxicity, and teratogeneicity; they may also be carcinogenic.

Animal pharmacokinetic data suggests that the botanical Desoris (LLL-3348) could be used once a day.

This is Lupin’s second IND Application based on herbal R&D; in early December, Lupin’s INDA for the prophylactic treatment of migraine was approved by the DCGI.